Corporate calendar for Lyell Immunopharma, Inc. (LYEL): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial,...
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | $159M | |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | ||
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 |
Stock Splits
| Date | Ratio |
|---|---|
| 2025-06-02 | 1:20 |
Price
| Price | $10.78 |
| Market Cap | $264M |
| Exchange | NASDAQ |
| Country | US |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 3 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 7 |
| Avg rating (1-5) | 0.29 |
Related companies: ACIU · ALDX · ALLO · AMRN · CABA · EDIT · GNLX
Explore sector: Healthcare · Biotechnology
More sections of LYEL: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks